Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 18:13:941839.
doi: 10.3389/fimmu.2022.941839. eCollection 2022.

HLA-associated outcomes in peanut oral immunotherapy trials identify mechanistic and clinical determinants of therapeutic success

Kanika Kanchan  1 , Gautam Shankar  1 , Michelle F Huffaker  2 , Henry T Bahnson  3   4 , R Sharon Chinthrajah  5 , Srinath Sanda  2 , Monali Manohar  5 , Hua Ling  6 , Justin E Paschall  6 , George Du Toit  7 , Ingo Ruczinski  8 , Alkis Togias  9 , Gideon Lack  7 , Kari C Nadeau  5 , Stacie M Jones  10 , Gerald T Nepom  3   4 , Rasika A Mathias  1
Affiliations

HLA-associated outcomes in peanut oral immunotherapy trials identify mechanistic and clinical determinants of therapeutic success

Kanika Kanchan et al. Front Immunol. .

Abstract

Rationale: Previous studies identified an interaction between HLA and oral peanut exposure. HLA-DQA1*01:02 had a protective role with the induction of Ara h 2 epitope-specific IgG4 associated with peanut consumption during the LEAP clinical trial for prevention of peanut allergy, while it was a risk allele for peanut allergy in the peanut avoidance group. We have now evaluated this gene-environment interaction in two subsequent peanut oral immunotherapy (OIT) trials - IMPACT and POISED - to better understand the potential for the HLA-DQA1*01:02 allele as an indicator of higher likelihood of desensitization, sustained unresponsiveness, and peanut allergy remission.

Methods: We determined HLA-DQA1*01:02 carrier status using genome sequencing from POISED (N=118, age: 7-55yr) and IMPACT (N=126, age: 12-<48mo). We tested for association with remission, sustained unresponsiveness (SU), and desensitization in the OIT groups, as well as peanut component specific IgG4 (psIgG4) using generalized linear models and adjusting for relevant covariates and ancestry.

Results: While not quite statistically significant, a higher proportion of HLA-DQA1*01:02 carriers receiving OIT in IMPACT were desensitized (93%) compared to non-carriers (78%); odds ratio (OR)=5.74 (p=0.06). In this sample we also observed that a higher proportion of carriers achieved remission (35%) compared to non-carriers (22%); OR=1.26 (p=0.80). In POISED, carriers more frequently attained continued desensitization (80% versus 61% among non-carriers; OR=1.28, p=0.86) and achieved SU (52% versus 31%; OR=2.32, p=0.19). psIgG4 associations with HLA-DQA1*01:02 in the OIT arm of IMPACT which included younger study subjects recapitulated patterns noted in LEAP, but no associations of note were observed in the older POISED study subjects.

Conclusions: Findings across three clinical trials show a pattern of a gene environment interaction between HLA and oral peanut exposure. Age, and prior sensitization contribute additional determinants of outcomes, consistent with a mechanism of restricted antigen recognition fundamental to driving protective immune responses to OIT.

Keywords: HLA; desensitization; oral immunotherapy; peanut allergy; remission; tolerance.

PubMed Disclaimer

Conflict of interest statement

GL reports holding stock and stock options in DBV Technologies. HB has provided statistical consulting to DBV Technologies (paid to Benaroya Research Institute). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Du Toit G, Roberts G, Sayre PH, Bahnson HT, Radulovic S, Santos AF, et al. . Randomized trial of peanut consumption in infants at risk for peanut allergy. N Engl J Med (2015) 372(9):803–13. doi: 10.1056/NEJMoa1414850 - DOI - PMC - PubMed
    1. Winters A, Bahnson HT, Ruczinski I, Boorgula MP, Malley C, Keramati AR, et al. . The MALT1 locus and peanut avoidance in the risk for peanut allergy. J Allergy Clin Immunol (2019) 143(6):2326–9. doi: 10.1016/j.jaci.2019.02.016 - DOI - PMC - PubMed
    1. Kanchan K, Grinek S, Bahnson HT, Ruczinski I, Shankar G, Larson D, et al. . HLA alleles and sustained peanut consumption promote IgG4 responses in subjects protected from peanut allergy. J Clin Invest (2022) 132(1):1–13. doi: 10.1172/JCI152070 - DOI - PMC - PubMed
    1. Kanchan K, Clay S, Irizar H, Bunyavanich S, Mathias RA. Current insights into the genetics of food allergy. J Allergy Clin Immunol (2021) 147(1):15–28. doi: 10.1016/j.jaci.2020.10.039 - DOI - PMC - PubMed
    1. Jones SM, Kim EH, Nadeau KC, Nowak-Wegrzyn A, Wood RA, Sampson HA, et al. . Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the immune tolerance network IMPACT trial): a randomised placebo-controlled study. Lancet. (2022) 399(10322):359–71. doi: 10.1016/S0140-6736(21)02390-4 - DOI - PMC - PubMed

Publication types